RUNX3 has been found elevated in renal cancer and is associated with shorter progression-free survival, and high RUNX3 expression predicts a greater benefit of IO/TKI (immune checkpoint inhibitor combined with a lorosine kinase inhibitor) therapy compared to TKI monotherapy (43). Here, RUNX3 is linked to renal carcinoma.